Type 2 Diabetes: What’s the Scientific Evidence for the Role of the Gut Microbiome?
Sponsored by Pendulum Therapeutics
An expanding body of evidence demonstrates that pathophysiologic changes occur in the gut microbiome of people with type 2 diabetes. These changes, along with potential management modalities, including the use of novel probiotics, will be discussed. Presenters include a renowned endocrinologist and a registered dietitian nutritionist, certified diabetes care and education specialist well versed in this science. Sufficient time will be allotted for Q and A.
Presented on: Tuesday, December 8, 2020 1 pm CT, 2 pm ET
Orville Kolterman, MD
Today Orville Kolterman serves as the chief medical officer of Pendulum Therapeutics. He has been involved in diabetes care for nearly 50 years. He received his MD from University of Chicago and did his endocrinology training at Stanford School of Medicine. Dr. Kolterman is an internationally respected diabetes expert and has successfully brought four glucose-lowering pharmaceuticals from research trials to market. He also served as chief medical officer of Amylin Pharmaceuticals.
Kristin Neusel, MS, RD, LD, CDCES
Kristin Neusel is currently the Diabetes Education and Patient Engagement Manager with Pendulum Therapeutics. Prior to this role Kristin was the Senior Clinical Educator for Aegerion Pharmaceuticals focusing on glucose and lipid metabolism for people with rare and ultra-rare genetic diseases. This is where her passion for diabetes-focused therapeutics grew and she became a CDCES. Kristin completed both her undergraduate and graduate degrees in Human Nutrition and Dietetics from Southern Illinois University with a minor in Spanish. After serving in several roles on the board of the St. Louis Academy of Nutrition and Dietetics, she is now president of this organization.
Credits: 1 CEU Approved
1. Detail the pathophysiologic changes that occur in the gut microbiome of people with type 2 diabetes, including the role of butyrate, a short chain fatty acid, in the glucagon-like peptide 1 (GLP-1) physiologic pathway.
2. Delineate the beneficial functions of the gut bacteria that may be missing in the gut microbiomes of people with type 2 diabetes.
3. Detail the science and evidence for the use of a medical probiotic formulated to improve gut health and glycemic management in people with type 2 diabetes.
Access Webinar Here
Not a DDPG DPG member? The investment in DDPG membership will pay for itself if you attend just one webinar! With DDPG membership you receive ~15 CEUs throughout the membership year (with Webinars and through “On the Cutting Edge”) approximately $2/ CEU!
Why not join today and significantly reduce the cost of CEUs without the expense of traveling?